Skip to main content
Fig. 1 | BMC Urology

Fig. 1

From: Impact of next-generation hormonal agents on treatment patterns among patients with metastatic hormone-sensitive prostate cancer: a real-world study from the United States, five European countries and Japan

Fig. 1

Initial mHSPC treatment received at time of data collection, split by regions. Note: Individual data labels that were < 3% are not shown. ADT: androgen deprivation therapy; EU5: France, Germany, Italy, Spain, and the United Kingdom; mHSPC: metastatic hormone-sensitive prostate cancer; NHA: novel hormonal agents (abiraterone, enzalutamide, apalutamide, darolutamide); UK: United Kingdom; US: United States. Other combinations included ‘Other NHAs’ that were being used in 1.7% of patients overall across treatment lines; ‘Other chemotherapy’ that was being used in 0.4% of patients overall across treatment lines; ‘Other combinations including NHA’ that were being used in 1.5% of patients overall across treatment lines; ‘Chemotherapy combination’ which was being used in 0.3% of patients overall across treatment lines; ‘Any other treatment combinations’ that were being used in 1% of patients overall across treatment lines

Back to article page